Starting March 26, cola lovers everywhere will be invited to get a first taste of new Pepsi NEXT, a game-changer in the cola category and the first to deliver real cola taste with 60% less sugar than Pepsi-Cola.
“We’re on a mission to get consumers to experience the real cola taste of Pepsi NEXT for themselves,” said Angelique Krembs, Vice President TM Pepsi Marketing. “We’re excited that after years of research and development, we’ve unlocked the great taste of Pepsi NEXT, the choice for consumers who want real cola taste with less sugar.”
Research has shown that there is a segment of consumers who are resistant to both regular, full-sugar cola and diet cola offerings. These consumers love the taste of Pepsi but they don’t believe you can achieve full-flavor taste with a diet cola. The launch of Pepsi NEXT is intended to fulfill this unmet need in the category.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54979-pepsi-next
Fluke Corporation, the global leader in portable electronic test and measurement technology, introduces the new Fluke® 62 Max and 62 Max+ Infrared Thermometers. These rugged, accurate, easy-to-use test tools are dust, water and drop resistant, making them ideal for the harsh conditions faced by technicians in electrical, service, HVAC, process, industrial and facilities maintenance applications.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56193-new-fluke-62-max-infrared-thermometers-dust-water-and-drop-protection
To help professionals and do-it-yourselfers weatherize and make home improvements faster, DAP Products Inc. today announced the introduction of the newest innovation in premium sealants. The newly-formulated DAP® 3.0™ line establishes first-to-market technology with high-performance sealants that are both paintable and water resistant in 30 minutes. In addition, DAP® 3.0™ is low odor, VOC-compliant (volatile organic compounds) and backed by a lifetime guarantee.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57526-dap-introduces-newest-innovation-in-high-performance-sealants
According to the National Fire Protection Association, nuisance alarms or “false” alarms, are the leading cause for intentionally disabled smoke alarms in America. Unfortunately, each fire season also brings reports of serious injuries and deaths, and roughly two-thirds of home fire deaths happen in houses with no smoke alarms or working smoke alarms. A recent study from the University of Maryland’s School of Fire Protection Engineering shows that consumers now have a better choice when it comes to reducing nuisance alarms in their home. The new, patented IoPhic® smoke and fire alarm from Universal Security Instruments using smart microprocessor technology was proven to be more resistant to false or nuisance alarms than competitors.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58136-universal-security-instruments-iophic-smoke-fire-alarms-prevent-nuisance
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
For Spring-Summer 2016, Maison Roger Vivier has entrusted one of its icons line to celebrity Stylist Camille Seydoux: Prismick. A friend of the house, this young woman has dreamed up a version all of her own: a capsule collection entirely in denim.
Six pieces make up this perfect wardrobe: platform sandals, ankle boots, a shoulder bag, a bucket bag, a backpack and a sneaker. Camille melds her creativity with the Roger Vivier legacy. She says:
"We decided that my collection would be dedicated to the Prismick line created in 2012, which is one of my favourites. I began by attentively exploring my own Prismick bag, which is in a melting fade of black and grey. I wanted to work on the idea of facets that make up grades of shading. I looked through the Maison's archives and then I thought of denim. It's a fabric that naturally burnishes. Denim is both classic and modern, and significant detail, is very resistant."
Camille grew up in fashion's inner circle. She opened her own art gallery at the age of 25. Today, she is revolutionising the role of stylist by working hand-in-hand with couture house studios to design bespoke dresses for actresses. For Roger Vivier, she brought her own touch of impertinence: "Denim can be worn with everything and can tone down an outfit. This capsule collection shakes up the look. "
To view the multimedia release go to:
http://www.multivu.com/players/uk/7776151-prismick-denim-camille-seydoux-roger-vivier/
MAKE UP FOR EVER, the professional makeup line of innovative and artistic products created for professional stage artists, makeup artists and makeup enthusiasts, announces a worldwide artistic collaboration with global pop sensation CHARLI XCX and reveals its new AQUA XL EYE PENCIL campaign.
CHARLI XCX’s bold, artistic and energetic stage presence exemplifies the creative spirit of MAKE UP FOR EVER and the performance of the AQUA XL collection. In 2016, MAKE UP FOR EVER joins CHARLI XCX in all her performances and artistic creations, from her live tour to makeup artistry for her video clips. A virtuoso of words and sound, CHARLI XCX has written several international hit songs including her double platinum single, “Boom Clap,” alongside co-penning music for renowned artists; Grammy nominated “Fancy” (Iggy Azalea), triple platinum selling “I Love It” (Icona Pop) and “Same Old Love” (Selena Gomez).
The AQUA line, upon which performers and their makeup artists have long relied, has become AQUA XL, taking the limits of makeup performance to new levels. MAKE UP FOR EVER is revamping one of its iconic products with a new high-performance formula: AQUA XL EYE PENCIL, the first of the AQUA XL line and specially designed for performers’ needs. AQUA XL EYE PENCIL are stage-proof and offer flawless makeup results, incredible stay-on power and high color intensity. As comfortable as it is easy to apply, the AQUA XL EYE PENCIL’s long wear waterproof formula is resistant to all stage conditions and perfect for real life-use.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7792251-make-up-for-ever-teams-up-with-charli-xcx/
Q&Q SmileSolar, known for its fun, color-driven and eco-friendly watches, unveils a digital campaign video filmed and animated by Cait Davis of Springtime Jellyfish. The video brings the brand’s core values to life in a fresh, modern way. Watches are available to purchase via the brand’s online store at store.smile-qq.com.
The Q&Q SmileSolar hero video highlights two of the brand’s most popular styles – the 20 Bar ($60 retail) and Mini ($40 retail) - that are completely solar-powered, keeping them operating up to approximately three-and-a-half months after one single charge. The watches are also all eco-friendly – the strap and case incorporate recycled materials – and each have a durable water-resistant casing as well.
The video also gives nod to the brand’s commitment to Table for Two, a non-profit that delivers school meals to children in Africa and Asia. A percentage of sales from each watch goes to support the cause. To date, Q&Q has donated over 131,000 meals.
To view the multimedia release go to:
https://www.multivu.com/players/English/7886551-q-and-q-smilesolar-hero-video
Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.” And with social media profile images becoming more important than ever, there is interest in looking one’s best.
Submental fullness due to fat beneath the chin can impact a broad range of both men and women and because the condition can be genetic and resistant to diet and exercise. But there’s KYBELLA®, the first and only FDA-approved injectable treatment that is available by prescription only, that has been proven to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells in the treatment area. In two pivotal clinical studies for KYBELLA®, reductions in submental fat volume were observed more frequently in the KYBELLA® treated group of 514 patients compared to the placebo group (508 patients) as measured by both clinician and patient ratings. In addition, visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were evaluated using a 6-question survey and 79% of 1 and 2-grade composite responders reported satisfaction after 12 weeks post final treatment compared with 33.6% of patients who received placebo.
To view the multimedia release go to:
http://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
A ten-month clinical trial at Sentara Leigh Hospital in Norfolk, Virginia has determined that hard surfaces and linens infused with copper oxide compounds contributed to an 83% reduction in C-difficile and a 78% overall reduction in a host of multi-drug resistant organisms (MDROs) including C-diff, MRSA and VRE in a real-world clinical environment. These results occurred in a hospital with a robust protocol for managing infection risk certified by the health care accrediting body DNV-GL Healthcare.
The results of the trial were published in the peer-reviewed American Journal of Infection Control on Sept. 28, 2016 and will be presented at the annual conference of the Infectious Disease Society of America in New Orleans, Louisiana on October 27, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7955751-sentara-healthcare-infections-copper-clinical-trial/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
